Full-Time

Vice President

Market Access

Posted on 11/21/2025

Freenome

Freenome

201-500 employees

Blood-based multiomics cancer detection tests

Compensation Overview

$262.6k - $417k/yr

+ Cash Bonuses + Pre-IPO Equity

Daly City, CA, USA

Remote

SF Bay Area residency a plus; remote role with up to 30% travel.

Category
Business & Strategy (2)
,
Requirements
  • Bachelor's degree
  • 15+ years of commercial experience in diagnostics, pharmaceuticals, or biotech; diagnostics experience required
  • 10+ years in Market Access with direct responsibility for pricing, reimbursement, or policy across the product lifecycle
  • Experience in cancer or preventative screening, primary care, oncology, and/or consumer sectors
  • In-depth knowledge of the healthcare ecosystem, including economics, policy, and the regulatory environment in the United States
  • Familiarity with customer types such as health care professionals, patients, payers, integrated delivery networks, and their business models
  • Proven track record in creating and executing access and reimbursement strategies
  • Ability to build pricing and reimbursement models for diagnostics
  • Knowledge of regulatory guidelines and compliance requirements
  • Highly collaborative with strong interpersonal skills and relationship-building capabilities
  • Entrepreneurial mindset with a proactive approach to problem-solving
  • Ability to craft and convey the company’s story compellingly to various audiences
Responsibilities
  • Spearhead the development and execution of market access strategies to enhance patient access, secure reimbursement, and encourage product adoption
  • Lead coding, coverage, and pricing initiatives to ensure reimbursement for our colorectal cancer screening test upon FDA approval and future product pipeline
  • Craft access, reimbursement, and contracting strategies for various payer segments and geographies, aligning with our go-to-market roadmap
  • Perform pricing analysis and modeling to establish optimal pricing and contracting that maximizes patient access and revenue
  • Identify and build out the appropriate team to support our market access goals
  • Collaborate with commercial, finance, and medical teams to develop value propositions, payer messaging, pricing strategies and evidence generation plans that support our market access goals
  • Offer strategic leadership on policy issues, access-related market dynamics, and reimbursement
  • Partner with Freenome’s Revenue Cycle/Billing team to ensure the Average Selling Price for each Freenome product is optimized through effective pricing strategies, payer negotiations, and claims and appeals management
  • Monitor and report on healthcare policies, regulations, and trends that affect market access
  • Engage with payers, government entities, and stakeholders to inform market access strategies
  • Influence healthcare policies and reimbursement practices through engagement with policymakers and advocacy groups
  • Conduct market research to understand the payer landscape and policy trends
  • Lead market access launch readiness, including building out the necessary team to support our go-to-market plan
  • Work with internal stakeholders to ensure market access strategies are in sync with business goals
  • Develop KPIs to monitor the effectiveness of market access strategies
  • Collaborate with Marketing, Legal, and Regulatory Affairs to drive coordinated payer engagement
Desired Qualifications
  • SF Bay Area residency is a plus but not mandatory
  • An MBA is advantageous but not essential
  • Experience with pricing, coding and coverage for Advanced Diagnostic Laboratory Tests (ADLTs)
  • Experience in IVD or laboratory developed test (LDT) market access
  • Experience in market research, analysis, or planning in the pharmaceutical, biotechnology, or related industry is beneficial
  • Experience leading a reimbursement and billing team is a plus

Freenome develops non-invasive blood tests for early cancer detection by combining genomics and proteomics to identify cancer signals in blood. The tests are sold to healthcare providers and research institutions and are also used in clinical trials and collaborations. The process involves analyzing a blood sample with proprietary algorithms to assess cancer risk and guide follow-up diagnostics. By integrating multiple data types and pursuing large-scale trials, Freenome aims to make early cancer screening routine and improve patient outcomes, with a focus on expanding colorectal cancer testing.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • SimpleScreen CRC FDA approval expected H2 2026 unlocks $2B+ colorectal cancer screening market.
  • SPAC merger with Perceptive Capital Solutions provides $330M funding for multi-cancer pipeline expansion.
  • Roche $75M investment and $200M+ deal validates technology and accelerates global commercialization.

What critics are saying

  • Exact Sciences exclusive U.S. rights eliminate Freenome's domestic revenue and commercialization control.
  • SPAC merger failure depletes cash reserves after 100-employee layoffs, halting product launches.
  • Guardant Health's Shield test captures 70% market share, undercutting Freenome's multiomics platform.

What makes Freenome unique

  • Multiomics platform analyzes DNA, immune, and metabolic signals for earliest cancer detection.
  • Secured exclusive U.S. colorectal cancer rights deal with Exact Sciences worth up to $775 million.
  • Roche partnership enables kitted decentralized testing and Axelios sequencing technology evaluation internationally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-3%
BioPharma Dive
Nov 20th, 2025
Roche inks deal for rights to Freenome cancer tests outside US

Roche inks deal for rights to Freenome cancer tests outside US. Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round. Dive brief: * Roche has struck a deal to commercialize Freenome's cancer screening technology outside the U.S., the companies said Tuesday. * Freenome will receive a $75 million investment from Roche as part of a deal that could be worth more than $200 million. * The deal positions Freenome, which currently uses Illumina machines, to evaluate Roche's new sequencing device. In a note to clients, Leerink Partners analysts said they see no near- to medium-term impact on Illumina. Dive insight: Nearing pre-market approval of its colorectal cancer blood-based screening test, Freenome has struck deals to support its commercialization in recent months. In August, Exact Sciences agreed to pay Freenome $75 million upfront, plus up to $700 million in milestones, for U.S. rights to current and future versions of the test. Roche's deal covers the marketing of "kitted" tests in areas outside of the U.S. Kitted tests package the software and assay to enable decentralized test processing and analysis, eliminating the need for a singular large processing lab. Freenome has retained rights to centralized testing outside the U.S. Roche, meanwhile, could shell out milestone payments and royalties on ex-U.S. sales. The $75 million equity investment increases Roche's stake in Freenome after leading a $254 million financing round last year. Other Roche investments, such as positions backing Flatiron Health and Foundation Medicine, have resulted in acquisitions. Freenome already uses Roche's Elecsys technology for multiple types of analyses. Under the new deal, Freenome will study the potential for Roche's "sequencing by expansion" technology to enhance its cell-free DNA cancer screening tests. Freenome will also gain access to Roche plasma sample cohorts to support the development of personalized screening tests for multiple types of cancer. Roche unveiled its sequencing technology in February and provided more information at its diagnostics day in May. At that event, Josh Lauer, the company's head of molecular labs, said "speed is something very unique about this platform and something no other short-read sequencer is able to match." Leerink analysts evaluated the threat the technology - which Roche has branded Axelios - poses to Illumina in light of the Freenome agreement. The analysts said the deal "highlights Roche's long-term strategy for Axelios - a clinical box for running NGS kits, similar to with their prior success in IVD kits." Yet it will take a few years of testing and refinement to ready Axelios for clinical sequencing, they added. "We don't expect other oncology Dx companies to jump to try Roche SBX in [the] U.S. or internationally given their new assays are already entrenched and some are FDA approved on [Illumina] sequencers," the analysts said in a note to investors. "Switching costs and reliability needs are high and clinical Dx companies indicate they won't entertain the switch without a clear value proposition."

Freenome
Nov 19th, 2025
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.

– Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – – Deal potentially […]

finanzen.net
Nov 18th, 2025
Freenome, Roche Partner in $200M Deal

Freenome has partnered with Roche in a deal potentially worth over $200 million to commercialize its cancer screening technology in international markets. The agreement includes a $75 million equity investment from Roche and focuses on developing "kitted" tests for decentralized processing. Freenome will also evaluate Roche's Sequencing by Expansion technology. This collaboration aims to enhance Freenome's multiomic blood-based cancer screening platform and expand its global reach.

PR Newswire
Jun 2nd, 2025
Freenome Announces Jama Publication Of Data From Pivotal Study Of Its Blood-Based Test For Colorectal Cancer

– PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS coverage requirements for sensitivity and specificity in the intended use population –. – FDA premarket approval submission is underway, with completion anticipated mid-2025 –. BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in JAMA.1 The publication presents findings from the largest prospective study of a blood-based screening test for colorectal cancer (CRC), involving 48,995 average-risk adults aged 45 to 85 who underwent a routine colonoscopy following a blood draw

Health Technology Insights
May 21st, 2025
Freenome Appoints Linh H. Le as Chief Financial Officer

Freenome appoints Linh H. Le as chief financial officer.

INACTIVE